Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
2020 ◽
Vol 157
(2)
◽
pp. 379-385
◽
Keyword(s):
Phase Ib
◽